# A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer

> **NCT01130337** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 36 (actual)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Capecitabine [Xeloda]
- **DRUG:** Oxaliplatin
- **DRUG:** Trastuzumab [Herceptin]

## Key facts

- **NCT ID:** NCT01130337
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-06
- **Final completion:** 2014-06
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2015-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01130337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01130337, "A Study of Capecitabine [Xeloda] in Combination With Trastuzumab [Herceptin] and Oxaliplatine in Patients With Resectable Gastric Cancer". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01130337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*